Loretta Nastoupil, MD, and John Burke, MD, discussed treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
News
Advertisement
Short-term morphological rescue was seen after voretigene neparvovec-rzyl treatment.
Advertisement
The executive vice president of research and development at Jasper Therapeutics discussed how JSP191 is designed to be better-tolerated than current conditioning regimens.
Abeona Therapeutics is seeking a path towards BLA filing based on the promising clinical data.
NT-501 previously received orphan drug and fast track status from the FDA and Neurotech will pursue approval in late 2022.
The company plans to use the mRNA platform it harnessed for its COVID-19 vaccine to develop the vaccine for malaria.
Advertisement
The first patient in CG Oncology's phase 2 study of CG0070 was dosed in December 2020.
Investigators found that reactivating the CaMKII enzyme could protect against further vision loss.
Bluebird Bio plans to submit its biologics license application in the US by mid 2021.
The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.
Advertisement
The chief technology and chief executive officer of Mustang Bio discussed the company’s integrated approach to drug development.
Experts discussed their recommendations for second-line treatment options for patients with DLBCL.
The co-founder, president, and chief executive officer of Solid Biosciences, whose own son has DMD, discussed challenges in developing gene therapies for DMD.
Stephen J. Schuster, MD, discussed tisagenlecleucel's efficacy and safety over other available treatments for relapsed/refractory FL.
The chief executive officer and co-founder of Flexion Therapeutics discussed the company’s pain-focused pipeline, which includes a gene therapy that targets inflammation.
A drop in endogenous Factor VIII expression was observed from treatment to 5-year follow-up despite continued demonstration of efficacy.
Joseph Sullivan, MD, and Elaine C. Wirrell, MD, discuss new developments for the treatment of Dravet syndrome beyond seizure control including gene editing and therapy.
The chief technology officer of Mustang Bio discussed the company’s approach and future plans in CAR T production.
Encouraging results from the phase 1 BrainChild-01 trial were recently published.
Heterogeneity in the cellular and molecular features of CAR T-cell products contributes to variation in efficacy and toxicity follow treatment with axicabtagene ciloleucel.
huCART19 is designed to yield longer remission rates for pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
The hematologist/oncologist from the Harold C. Simmons Comprehensive Cancer Center discussed the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.
MCO-010 is designed to deliver multi-characteristic opsin to retinal cells.
Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio discussed the company’s lead and second program.
The professor of medicine at the UC Davis Comprehensive Cancer Center discussed Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.
Three patients continue to show improvements in BCVA 3 years post-treatment.
The co-founder, president, and chief executive officer of Solid Biosciences, whose own son has DMD, discussed some challenges the company is facing.
The physician from the Dana-Farber Cancer Institute discussed the uptake of novel therapies in heavily pretreated multiple myeloma.
The phase 1b KEYNOTE-B79 trial of CYAD-101 for mCRC is expected to initiate in Q4 2021.
The president, chief executive officer, and director of Mustang Bio discussed the company’s pipeline.
